Who are Exposure to Triptan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imitrex®, ALMOTRIPTAN MALATE, naratriptan HCl, Sumatriptan and Naproxen sodium, conventional migraine drug treatment, almotriptan or pseudoephedrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/exposure-to-triptan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Exposure to Triptan — Competitive Intelligence Brief

Exposure to Triptan (Exposure to Triptan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan. Area: Neurology.

phase 2 Triptan 5-HT1B and 5-HT1D receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Exposure to Triptan (Exposure to Triptan) — Assistance Publique Hopitaux De Marseille. Triptans are a class of drugs that work by stimulating serotonin receptors in the brain, leading to the dilation of blood vessels and the relief of migraine symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Exposure to Triptan TARGET	Exposure to Triptan	Assistance Publique Hopitaux De Marseille	phase 2	Triptan	5-HT1B and 5-HT1D receptors
Imitrex®	Imitrex®	Teva Pharmaceuticals USA	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B and 5-HT1D receptors
ALMOTRIPTAN MALATE	ALMOTRIPTAN MALATE		marketed	Triptan	5-HT1B/1D receptors	2001-01-01
naratriptan HCl	naratriptan HCl	Cady, Roger, M.D.	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Sumatriptan and Naproxen sodium	Sumatriptan and Naproxen sodium	POZEN	marketed	Triptan/NSAID combination	5-HT1B/1D receptors (sumatriptan); COX-1/COX-2 (naproxen sodium)
conventional migraine drug treatment	conventional migraine drug treatment	Birjand University of Medical Sciences	marketed	Triptan, ergot alkaloid, or NSAID (class varies by specific agent)	5-HT1B/1D receptors (triptans); COX inhibition (NSAIDs); or alpha-adrenergic/serotonergic receptors (ergots)
almotriptan or pseudoephedrine	almotriptan or pseudoephedrine	Clinvest	marketed	Triptan + sympathomimetic decongestant combination	5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan class)

· 1 drug in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
HCA Florida North Florida Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exposure to Triptan — Competitive Intelligence Brief. https://druglandscape.com/ci/exposure-to-triptan. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab